Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. (historically ENZ on the NYSE and later ENZB on OTCQX) generated a steady stream of corporate and financial news as a life sciences company focused on labeling and detection technologies from DNA to whole cell analysis. Its disclosures highlight a portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins that support translational research and drug development in areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry.
The company’s news flow has included quarterly and annual financial results, where Enzo reported on revenue trends in its Life Sciences division, gross margin performance, operating loss or income, and the impact of cost containment initiatives and product mix. These releases often discussed demand from drug development and cell and gene therapy market segments, as well as the use of non-GAAP measures like Adjusted net loss and Adjusted EBITDA, with reconciliations provided in accompanying tables.
Enzo’s announcements have also covered strategic and corporate actions, such as its exit from the clinical lab business, focus on life science tools, workforce and cost initiatives, and product life cycle management, including removal of non-performing SKUs and new product launches. Governance and corporate updates have included officer appointments, board changes, and shareholder meeting results.
In 2025, the news record shows important capital markets and M&A developments, including NYSE non-compliance notices, a voluntary delisting from the NYSE, transfer of trading to OTCQX, and the subsequent agreement and completion of a merger with Bethpage Parent, Inc., after which Enzo became a wholly owned subsidiary and its shares ceased trading. For readers reviewing ENZ or ENZB news, this page serves as a historical archive of earnings releases, strategic reviews, listing changes, and merger-related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Enzo Biochem, a biosciences and diagnostics company, has scheduled a Special Meeting of Shareholders on May 22, 2023, to vote on the proposed sale of its clinical laboratory assets to Labcorp. The meeting will address the Asset Purchase Agreement dated March 16, 2023, which outlines the terms of the sale, including the assignment of certain liabilities. Shareholders are urged to vote by proxy before the meeting. The company has filed a proxy statement with the SEC detailing the transaction to inform shareholders adequately. Enzo Biochem is recognized for its innovative diagnostic technologies and holds a significant intellectual property portfolio.
Enzo Biochem (NYSE:ENZ) filed its Q2 FY23 report, revealing revenues of $16.3 million, marking a 52% decrease from $34.0 million in Q2 FY22 due to reduced COVID testing. The Clinical Labs segment contributed $8.8 million, a 63% decline year-over-year, while Enzo Life Sciences generated $7.5 million, stabilizing near Q2 FY22 levels. Notably, January 2023 saw the firm's second-highest monthly revenue in over a decade. The company entered an asset purchase agreement for its Clinical Labs assets, aiming to unlock shareholder value and optimize its remaining assets. No financial call was held for this quarter.